From Wikipedia, the free encyclopedia
Chemical compound
Globalagliatin
|
|
Other names | SY-004 |
---|
|
Legal status |
|
---|
|
(1R,2S)-2-Cyclohexyl-1-(4-cyclopropylsulfonylphenyl)-N-[5-(2-pyrrolidin-1-ylethylsulfanyl)-1,3-thiazol-2-yl]cyclopropane-1-carboxamide
|
CAS Number | |
---|
PubChem
CID | |
---|
|
Formula | C28H37N3O3S3 |
---|
Molar mass | 559.80 g·mol−1 |
---|
Globalagliatin (SY-004) is a
glucokinase activator developed by Yabao Pharmaceutical Group for type 2 diabetes.
[1]
[2]
[3]
-
^ Zhao, Yuqing; Xie, Lijun; Zhang, Hongwen; Zhou, Sufeng; Liu, Yun; Chen, Juan; Wang, Lu; Wang, Libin; Zhuo, Lang; Wang, Yarong; Ou, Ning; Shao, Feng (February 2022). "Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of SY-004, a Glucokinase Activator, in Healthy Chinese Adults: A Randomized, Phase Ia, Single-Ascending Dose Study". Clinical Therapeutics. 44 (2): 269–281.
doi:
10.1016/j.clinthera.2021.12.009.
PMID
35093240.
S2CID
246416557.
-
^ Zheng, Shuai; Shao, Feng; Ding, Yu; Fu, Zhenzhen; Fu, Qi; Ding, Sijia; Xie, Lijun; Chen, Juan; Zhou, Sufeng; Zhang, Hongwen; Zhou, Hongwen; Chen, Yang; Sun, Caixia; Zhu, Jing; Zheng, Xuqin; Yang, Tao (December 2020). "Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study". Clinical Drug Investigation. 40 (12): 1155–1166.
doi:
10.1007/s40261-020-00971-x.
PMID
33125674.
S2CID
225983121.
-
^ Yang, Wenjia; Wu, Han; Cai, Xiaoling; Lin, Chu; Jiao, Ruoyang; Ji, Linong (8 May 2023).
"Evaluation of efficacy and safety of glucokinase activators—a systematic review and meta-analysis". Frontiers in Endocrinology. 14.
doi:
10.3389/fendo.2023.1175198.
PMC
10200948.
PMID
37223016.